0 STEOCALCIN (OC) and osteopontin (OP) are two major noncollagenous calcium binding proteins in bone (1). During development of the osteoblast phenotype, osteopontin is expressed during the period of active proliferation and decreases postproliferatively, and expression is up-regulated in mature osteoblasts. In contrast, osteocalcin is expressed only postproliferatively in mature osteoblasts with the onset of extracellular matrix mineralization (2). In ROS 17/2.8 osteosarcoma cells, however, both osteocalcin and osteopontin are constitutively expressed. Some evidence points to the involvement of both proteins in bone turnover; for example, both proteins bind to hydroxyapatite and are regulated by 1,25-(OH),D, and TGFP. In addition, osteocalcin contributes to recruitment and/or differentiation of osteoclasts (3-5), and osteopontin appears to be important for attachment of the osteoclasts to the bone matrix (6, 7).
TGFP and 1,25-(OH),D, are involved in regulation of both bone formation and resorption. The steroid hormone 1,25-(OH),D, plays a principle role in calcium homeostasis and skeletal metabolism (S), as well as influences expression of genes related to establishment and maintenance of the bone cell phenotype (9). 1,25-(OH&D, exerts its primary effect by binding to its nuclear receptor, the vitamin D receptor (VDR), which belongs to the steroid / retinoid / thyroid hormone receptor superfamily (10) and acts via binding to distinct vitamin D response elements (VDRE). VDREs have been identified in several genes related to osteoblastic differentiation and function: human osteocalcin (11, 12) Gel mobility shift assay Nuclear extracts were prcparcd as previously described (40). In brief, cells were scraped in PBS, and after centrifugation the cell pellet was reconstituted in a hypotonic lysis buffer (10 mM HEPES, pH 7.5, 10 mM KCI, and 0.2 rnM EDTA) supplemented with 0.75 rnM spermidine, 0.15 rn,v spcrmine, 1 mu EGTA, 1 rnM dithiothreitol, and a broad spectrum of protease inhibitors: 0.2 mM PMSF, 70 pg/ ml N-tosyl-L-phenylalanine chloromethyl ketone, 10 g/ml trvpsin inhlbitor, 0.5 pg/ml lcupeptin, and 1 .O pg/ ml pepstatin.
Then O.& Nonidet I'40 was added, and cells were lysed using a dounce homogenizer.
After After transfection with an OC promoter construct of 1100 nucleotides, which contains the VDRE (pOCZCAT; Fig. 2A ), we observed a 4-to 6-fold decrease in basal CAT activity in response to both TGFP, and TGFP,. 1,25-(OH)zD, increased basal CAT activity &fold in 24 h. This increase was inhibited 20-to 30-fold after coincubation with either TGFP, or TGFP,. Thus, in addition to a significant inhibition of basal transcription, both TGFP subtypes abrogated 1,25-(OH),D, enhanced OC transcription.
To ascertain the extent to which TGFP effects on OC depend on VDRE sequences, ROS 17/2.8 cells were transfected with a construct in which the VDRE was deleted (pB$ICAT; Fig. 28 ). As expected, the construct did not respond to 1,25-(OH),D,.
TGFP, or TGFP, either alone or in the presence of 1,25-(OH),D, caused a 4-to 6-fold decrease in CAT activity. This inhibitory effect of TGFP on basal OC gene transcription on AP-1 activity in ROS 17/2.8 osteosarcoma cells. Gel shift assays were performed using AP-1 and SP-1 consensus sequences as the probes (Fig. 6) . The AI?-1 complex was increased after incubation with either TGFP or 1,25-(OH),D,, although the increase observed with TGFP was more pronounced than with 1,25-(OH),D,. Combined treatment caused a further enhancement of the AP-1 complex. No modulation of SP-1 binding activity was observed, which represents an internal control for protein quantitation. These findings indicate selectivity of the TGFP-and 1,25-(OH),D,-mediated signaling mechanisms that modulate nuclear transcription factor levels.
VDR protein levels are not rate-limiting for VDRE interactions in the presence of TGJ'P and 1,25-(OH)p, Because changes in VDR mRNA levels were observed after treatment with TGFP,, TGFP,, and 1,25-(OH),D, (Fig. 1) , we studied the effects of TGFP, and TGFP, in the absence or presence of 1,25-(OH),D, on VDR protein levels, as a possible mechanism for the inhibitory effects of TGFP on VDR/ RXR interactions at the OC and OP VDREs. We investigated the effect of TGFP on homologous up-regulation of the VDR by Western blot analysis. The results indicate that nuclear VDR levels are only detected after treatment with 1,25-(OH),D,, and that neither TGFP, nor TGFP, affects the 1, Fig. 7 indicates that TGFP inhibition of protein/DNA interactions at the VDRE is not the consequence of a reduction in the level of VDR protein.
We have found that TGFP alone causes a subtle enhancement of VDR levels in whole cell extracts after 24 h of treatment (P < 0.05). We have previously reported that the magnitude of this response is higher at 6 h after TGFP administration (37). The modestly elevated levels of VDR protein after 24 h of TGFP treatment therefore may represent a residual, and perhaps persistent, component of TGFP responsiveness. Our previous observation that TGFP enhances VDR levels in whole cell extracts as a component of an earlier response (i.e. 6 h) (37) and our that show that TGFP does not significantly influence homologously up-regulated levels of the VDR protein at 24 h are both consistent with a complex temporal regulatory mechanism for modulation of the VDR levels that may in part be compartmentalized.
Discussion
In this study we focused on gene regulatory mechanisms that control OC and OP expression, which are affected by the combined activities of 1,25-(OH),D, and TGFP. The basis of our studies is supported by previous studies (36,37) and our present findings, which show that TGFP inhibits the 1,25-(OH),D,-induced increase of both OC and OP mRNA levels. The physiological relevance of TGFP inhibition of the 1,25-(OH),D, enhanced expression of osteoblast-related genes is exemplified by decreased secretion of the osteocalcin protein, a major functional product of osteoblasts. In addition, by directly comparing the actions of TGFP, and TGFP,, we show that these agents exert identical effects on regulation of OC and OP gene expression. This finding is consistent with the observation that TGF&-and TGF&mediated cell signaling pathways operate via shared TGFP receptor classes (46). We tested the hypothesis that transcriptional repression of 1,25-(OH),D,-enhanced OC and OP gene expression may be achieved by modulating protein/ DNA interactions at the OC and OP VDREs. Transcriptional up-regulation of the OC gene by 1,25-(OH),D, requires the positive cis-acting VDRE, which interacts with VDR/RXR heterodimers in vitro (49, 54-57) and in vim (58). Our results show that TGFP inhibits both 1,25-(OH),D, enhancement of OC VDRE-mediated transcription and the 1,25-(OH&Da-dependent induction of VDR containing transcription factor complexes interacting with the OC-and OP-VDREs. Thus, we propose that TGF/3 may directly influence OC and OP gene transcription by modulating 1,25-(OH),D,-dependent protein/ DNA interactions at the OC and OP VDREs. This concept is supported by previous findings that another polypeptide regulator of OC transcription, TNF-a (59), influences 1,25-(OH),D,-regulated transcription by modifications of protein/ DNA interactions at the VDRE.
Regulation of the nuclear representation of VDR/RXR heterodimers may occur at multiple levels of control. For example, our results show that VDR mRNA levels are increased in a 1,25-(OH),D,-dependent manner, which is reflected by increased VDR protein levels as monitored by 
